Hims & Hers Health Target of Unusually Large Options Trading (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) saw unusually large options trading activity on Tuesday. Stock traders bought 28,871 call options on the company. This is an increase of 249% compared to the average daily volume of 8,272 call options.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 4,080 shares of Hims & Hers Health stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40. Following the sale, the insider now directly owns 154,345 shares of the company’s stock, valued at $1,548,080.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Hims & Hers Health news, insider Soleil Boughton sold 4,080 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40. Following the completion of the transaction, the insider now directly owns 154,345 shares in the company, valued at $1,548,080.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Melissa Baird sold 11,750 shares of Hims & Hers Health stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total value of $141,940.00. Following the transaction, the chief operating officer now directly owns 538,932 shares of the company’s stock, valued at $6,510,298.56. The disclosure for this sale can be found here. In the last three months, insiders sold 736,191 shares of company stock valued at $9,733,700. Company insiders own 31.63% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Entropy Technologies LP acquired a new stake in Hims & Hers Health during the 1st quarter worth approximately $1,386,000. ProShare Advisors LLC raised its holdings in shares of Hims & Hers Health by 10.0% in the first quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock valued at $344,000 after purchasing an additional 2,023 shares during the last quarter. Avantax Advisory Services Inc. bought a new stake in shares of Hims & Hers Health in the first quarter worth $156,000. Headlands Technologies LLC acquired a new position in Hims & Hers Health during the first quarter worth $228,000. Finally, Sei Investments Co. grew its holdings in shares of Hims & Hers Health by 206.9% in the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after acquiring an additional 37,890 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

HIMS has been the topic of several research analyst reports. Guggenheim increased their target price on Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Truist Financial boosted their target price on shares of Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a research note on Tuesday, February 27th. Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Leerink Partnrs reissued a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.07.

Hims & Hers Health Stock Down 1.5 %

HIMS stock opened at $12.16 on Thursday. Hims & Hers Health has a twelve month low of $5.65 and a twelve month high of $17.16. The business’s fifty day moving average is $14.01 and its 200-day moving average is $10.39. The company has a market cap of $2.61 billion, a P/E ratio of -107.91 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. During the same period last year, the company posted ($0.05) EPS. Hims & Hers Health’s revenue for the quarter was up 45.8% on a year-over-year basis. Research analysts anticipate that Hims & Hers Health will post 0.11 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.